Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Lymphedema
Phase Not Applicable
Enrollment 10000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The primary objectives of this study are twofold: 1) to detect and determine the level of symptoms, functional disability, and changes in quality of life that breast cancer patients experience from changes in their arms during and after treatment for breast cancer by collecting patient reported outcome measures, objective measurements, and clinical information in a prospectively maintained database and 2) to improve breast cancer-related lymphedema outcomes by early detection using objective measurements and symptoms assessments and assess these outcomes by maintaining the data in a database in order to contribute to the literature. The secondary aim of this study is to assess extracellular fluid content in the upper extremity, breast, and/or trunk of patients treated for breast cancer before, during, and after treatment in order to better understand the role of bioimpedance spectroscopy in lymphedema screening.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Other: Breast Cancer-Related Lymphedema Screening — All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.

Primary Outcomes

  • Upper extremity changes following treatment for breast cancer (1.5 to 5 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2009-08
Completion: 2026-12
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 10000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Massachusetts General Hospital
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Alphonse G Taghian, MD PhD (PRINCIPAL_INVESTIGATOR) - Massachusetts General Hospital
Contact Information
Study Contact:
Alphonse G Taghian, MD PhD
617-726-6050
ataghian@partners.org
Massachusetts General Hospital
Alphonse G Taghian, MD PhD
Massachusetts General Hospital
Interventions
  • Other: Breast Cancer-Related Lymphedema Screening — All patients enrolled in the trial will receive prospective BCRL screening from their pre-operative baseline throughout their breast cancer treatment process. All participants will be measured with perometry, bioimpedance spectroscopy, and patient-reported outcome measures.
Study Locations (1 sites)
Massachusetts General Hospital, Boston, Massachusetts 02134 United States
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of breast cancer * Ability to obtain physical positioning for perometry (e.g. abducting shoulder to 90 degrees) and BIS measurements (e.g. standing without aid) Exclusion Criteria: * Evidence of distant metastatic disease that may cause edema, * Previous breast cancer * History of lymphedema * Pregnancy at the time of accrual and/or cardiac implants (contraindications for BIS) * Medical conditions that cause fluid retention or swelling (e.g. axillary cancer recurrence, renal insufficiency, congestive heart failure).
Conditions Anatomic Stage I Breast Cancer AJCC v8, ...
Phase PHASE2
Enrollment 174
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well dose-reduced docetaxel combined with cyclophosphamide works in treating older women with early stage (stage I-III) HER2 negative breast cancer vulnerable to toxicity. Chemotherapy drugs, such as docetaxel and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Docetaxel and cyclophosphamide are commonly used, but is not well tolerated at the standard dose and can affect the way older patients feel physically and emotionally. Giving dose-reduced docetaxel combined with cyclophosphamide may be an effective treatment option and improve quality of life in vulnerable older women with stage I-III HER2 negative breast cancer.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Cyclophosphamide — Given IV
  • Drug: Docetaxel — Given IV
  • Other: Medical Chart Review — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Relative dose intensity (RDI) (At completion of 4 cycles, up to 12 weeks (each cycle is every three weeks))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2024-09-16
Completion: 2030-03-20
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 174 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI), Rising Tide Foundation
Principal Investigators:
  • Thanh Nga E Doan, MD (PRINCIPAL_INVESTIGATOR) - City of Hope Medical Center
Contact Information
Study Contact:
Thanh Nga Doan, MD
626-321-1845
tdoan@coh.org
Thanh Nga Doan
626-256-4673
tdoan@coh.org
City of Hope Medical Center
Thanh Nga Doan
City of Hope Medical Center
Interventions
  • Drug: Cyclophosphamide — Given IV
  • Drug: Docetaxel — Given IV
  • Other: Medical Chart Review — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (3 sites)
City of Hope Medical Center, Duarte, California 91010 United States
Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States
University of Rochester, Rochester, New York 14642 United States
Eligibility Criteria
Inclusion Criteria: * Ability to provided informed consent or a legally authorized representative is able to consent on behalf of the patient * Willing to answer questionnaires as part of their participation * Age: \>= 65 years by the time of study registration * Histologically or cytologically confirmed breast cancer(s) that is human epidermal growth factor receptor 2 negative (HER2-negative) per the most recent 2018 American Society of Clinical Oncology College of American Pathologists (ASCO CAP) guidelines relapsed/ refractory disease * Estrogen receptor and progesterone receptor immunohistochemistry (IHC) status must be known; any estrogen receptor (ER)/progesterone receptor (PR) status is eligible * Non-metastatic, invasive breast cancer (scans are not required to document non-metastatic disease- any staging work-up is up to the treating providers' discretion) * Recommended to have either standard dose neoadjuvant docetaxel, cyclophosphamide (TC) chemotherapy or adjuvant TC chemotherapy per their treating provider. Participant may be on immunotherapy concurrently with the protocol regimen at the discretion of the treating physician * Any surgery, nodal assessment, radiation, hormonal therapy is left up to the treating provider but should not occur concurrently with study therapy * Any patient who received pre-operative hormonal therapy and who is then recommended for neo/adjuvant chemotherapy is eligible, though hormonal therapy should be held during study treatment administration * For patients with bilateral or multifocal/multicentric breast cancers, the following criteria must be met to enroll: (1) both cancer are HER2 negative, AND (2) the provider feels the patient will benefit from TC for at least one of the cancers * Patients who do not speak or read English are eligible as long as adequate interpreter services are available or the surveys are available in the preferred language (i.e. the Geriatric Assessment \[GA\] and Patient Reported Outcomes \[PRO\] surveys are available in many languages) Exclusion Criteria: * Participants who have already received any chemotherapy for their current breast cancer * Patients with recurrent and/or metastatic disease will be excluded. Prior diagnoses of breast cancers (including ductal carcinoma in situ \[DCIS\]) are allowed, provided that the treating provider feels that the current cancer most likely represents a new primary breast cancer and not recurrent disease * History of allergic reactions attributed to compounds of similar chemical or biologic composition to cyclophosphamide and/or docetaxel * Past treatment with the regimen TC for prior breast cancer
Conditions Diabetes Mellitus Type 2, Breast Neoplas...
Phase Not Applicable
Enrollment 1000
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study aims to develop and validate an artificial intelligence (AI)-based predictive model to estimate the risk of incident onset of five major diseases or conditions: cardiovascular disease, type 2 diabetes mellitus, breast cancer, low back pain, and osteoarthritis, in adults aged 30 to 65 years. For each participant, an index date will be defined as the date of a prior health screening or another protocol-defined baseline clinical date. Incident disease status for each target disease or condition will be ascertained by retrospective review of electronic medical records for up to 10 years after the index date. The study integrates retrospective clinical, health screening, laboratory, imaging, and electronic medical record data with prospectively collected biospecimen, proteomic, genomic, questionnaire, lifestyle, and digital health data. Prospective study procedures will be completed over approximately 1 week, with up to 2 additional weeks if needed. By combining multimodal data, this study seeks to improve disease risk prediction and to identify clinical and biological factors associated with disease onset, ultimately supporting personalized risk stratification and preventive healthcare strategies.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Number of Participants With Incident Target Disease or Condition Identified Up to 10 Years After the Index Date (Up to 10 years after the index date)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-04-02
Completion: 2026-12-31
Eligibility
Age: 30 Years – 65 Years
Sex: ALL
Volunteers: true
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jae Yong Jeon, MD
Contact Information
Study Contact:
Jaeyong Jeon
+82-2-3010-3791
jyjeon71@gmail.com
Jaeyong Jeon
+82-10-9970-3791
jyjeon71@gmail.com
Seoul Asan Medical Center
Interventions
N/A
Study Locations (1 sites)
Seoul Asan Medical Center, Seoul, Seoul Special City 05505 South Korea
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 30 to 65 years. 2. Disease group: Participants with a confirmed diagnosis of at least one of the following conditions: type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain. 3. Healthy control group: Participants with no prior diagnosis of type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain. 4. No history or current diagnosis of major medical conditions that may affect study outcomes, including but not limited to chronic kidney disease or liver cirrhosis. 5. Ability to understand the study procedures and provision of written informed consent prior to participation. Exclusion Criteria: 1. Participants with incomplete or insufficient clinical or health screening data. 2. Participants considered inappropriate for study participation by the investigator.
Conditions Breast Cancer, Breast Cancer and Pregnan...
Phase Not Applicable
Enrollment 800
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study plans to learn more about the immune system's response to breast cancer in young women.

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Primary Outcomes

  • Progression Free Survival (Throughout study participation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2009-07-21
Completion: 2027-07
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Colorado, Denver
Principal Investigators:
  • Virginia Borges, MD, MMSc (PRINCIPAL_INVESTIGATOR) - University of Colorado, Denver
Contact Information
Study Contact:
Hannah Parris
720-848-4170
hannah.parris@cuanschutz.edu
Hannah Parris
720-848-4170
hannah.parris@cuanschutz.edu
University of Colorado Denver
Virginia Borges, MD, MMSc
University of Colorado Denver
Interventions
N/A
Study Locations (5 sites)
University of Colorado Denver, Aurora, Colorado 80045 United States
Denver Health Hospital Authority, Denver, Colorado 80204 United States
UCHealth Cherry Creek Medcial Center, Denver, Colorado 80206 United States
UCHealth Highlands Ranch Hospital, Highlands Ranch, Colorado 80129 United States
UCHealth Lone Tree Medical Center, Lone Tree, Colorado 80124 United States
Eligibility Criteria
Inclusion Criteria: 1. Females \>18. 2. Histological or cytological confirmation of breast cancer. 3. For patients diagnosed with needle core or excisional biopsy, formalin-fixed paraffin embedded tumor blocks or unstained slides should be available or planned to be available after upcoming procedure. 4. Patient should be willing to have fresh and/or fresh frozen tissue collected at time of core biopsy, definitive breast cancer surgery or clinically planned breast cancer metastasis biopsy/resection for research purposes as part of study procedures, if a procedure is in the future planning of the patient's treatment. 5. Any clinical stage allowed. 6. Written informed consent obtained prior to any initiation of study procedures in the case of subjects consented in clinic. Subjects consented outside of UCH, VVMC or SCC will be consented by phone and verbal informed consent will be obtained prior to any initiation of study procedures. 7. Women treated at UCH, VVMC or SCC may be pregnant. Other participants are excluded for safety reasons. 8. Women who have commenced or completed their breast cancer treatment may join this study by consenting to a retrospective tissue donation only consent of the protocol. 9. Women who receive their care at a facility other than UCH, VVMC or SCC may join this study. These women will be consented utilizing the phone consent and will receive a copy of the consent in the mail, or they will consent online and print a copy of their online consent. Exclusion Criteria: 1. Known significant autoimmune condition \[ie Lupus, Crohne's disease or Rhuematoid Arthritis\], chronic oral steroid use, use of systemic immunomodulatory prescription drugs for any medical condition. 2. The presence of other comorbid conditions known to significantly impact immune function, (such as: type I diabetes, uncontrolled adult onset diabetes, severe COPD, uncontrolled infection or known HIV infection.) 3. Underlying psychiatric condition which would, in the opinion of the investigator, preclude compliance with study requirements 4. Subjects with a history of other malignancy besides current diagnosis of breast cancer who were diagnosed and treated within the last 5 years are excluded, with exception of cervical cancer definitively treated more than 2 years ago or non-melanomatous skin cancer.
Conditions Breast Cancer
Phase NA
Enrollment 2700
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This study is investigating the feasibility of a digital tool called a chatbot for providing educational information about mammography through a tablet, computer, or phone. This study will recruit participants who recently had a mammogram with the University of Utah. Based on their mammography results, women will be placed into two cohorts using their BI-RADS category. Once mammogram results are available, patients will be randomized 1:1 to either usual care or usual care with chatbot. This study will randomly invite participants from four groups for focus group discussions (FGDs) based on their mammogram results and adherence to screening recommendations

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Chatbot — The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.

Primary Outcomes

  • Screening Adherence (up to 24 months from initiation of study intervention)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-11-19
Completion: 2028-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: true
Enrollment: 2700 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Utah
Collaborators: American Cancer Society, Inc.
Contact Information
Study Contact:
Anthony Ariotti
801-213-6542
anthony.ariotti@hsc.utah.edu
Elissa Ozanne, PhD
801-213-4130
Elissa.Ozanne@hsc.utah.edu
Huntsman Cancer Institute/ University of Utah
Elissa Ozanne, PhD
Huntsman Cancer Institute/ University of Utah
Interventions
  • Other: Chatbot — The Chatbot used in this study will be used after mammography to facilitate follow-up, answer patient questions, and provide information.
Study Locations (1 sites)
Huntsman Cancer Institute/ University of Utah, Salt Lake City, Utah 84108 United States
Eligibility Criteria
Inclusion Criteria: * Adult (equal to or above 18 years old) * English or Spanish speaking * Visit a mammography program for routine screening. Exclusion Criteria: * Patients who are currently in treatment for breast cancer * Patients who are not of 18 years of age. * Patients who don't speak English or Spanish * Men * Cognitive limitations that impede informed consent
Conditions Breast Cancer
Phase PHASE2
Enrollment 42
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The GATHER trial aim to evaluate the diagnostic performance of \[68Ga\]Ga-NOTA-anti-HER2-sdAb PET/CT in predicting pCR following neoadjuvant chemotherapy. This study is part of the development of new functional, non-invasive approaches with the aim of offering personalized therapeutic approaches.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Diagnostic Masking/blinding: None

Interventions / Regimen

  • Other: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography — Patients will undergo an \[68Ga\]Ga-NOTA-anti-HER2-sdAb PET/CT before neoadjuvant chemotherapy and 15 days prior the scheduled surgery

Primary Outcomes

  • Concordance rate between the response estimated by [68Ga]Ga-NOTA-anti-HER2-sdAb PET/CT and the invasive pathological complete response (2 weeks after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2026-07-15
Completion: 2028-03-01
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 42 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centre Henri Becquerel
Principal Investigators:
  • Florian Clatot, MD, PhD (PRINCIPAL_INVESTIGATOR) - Centre Henri Becquerel
Contact Information
Study Contact:
Florian Clatot, MD, PhD
+33232082981
florian.clatot@chb.uncancer.fr
Doriane Richard, PhD
+33232082985
doriane.richard@chb.unicancer.fr
Florian Clatot, MD, PhD
+33232082981
florian.clatot@chb.unicancer.fr
Centre Henri Becquerel
Interventions
  • Other: [68Ga]Ga-NOTA-anti-HER2-sdAb Positron Emission Tomography — Patients will undergo an \[68Ga\]Ga-NOTA-anti-HER2-sdAb PET/CT before neoadjuvant chemotherapy and 15 days prior the scheduled surgery
Study Locations (1 sites)
Centre Henri Becquerel, Rouen, France
Eligibility Criteria
Inclusion Criteria: * Female aged 18 years or older * Histologically proven HER2-positive early breast cancer, defined as IHC 3+ or IHC 2+ with ISH amplification * Indication for neoadjuvant chemotherapy combined with anti-HER2 targeted therapy followed by surgery, as determined by a multidisciplinary tumor board * ECOG performance status of 0 or 1 * Affiliated to or beneficiary of a social protection scheme * Written informed consent signed prior to any study-specific procedure Exclusion Criteria: * Pregnant or breastfeeding women * Patient not treated with curative intent * History of ipsilateral breast cancer treated by surgery and/or radiotherapy * Lobular histology * Known contraindication or hypersensitivity to \[68Ga\]Ga-NOTA-anti-HER2-sdAb or any of its radiopharmaceutical excipients * Known contraindication or hypersensitivity to \[18F\]F-FDG or any of its radiopharmaceutical excipients * Concurrent enrollment in another clinical trial evaluating radiopharmaceuticals * Patient under guardianship, curatorship, or judicial protection * Patient deprived of liberty * Inability to understand the study or comply with trial constraints due to linguistic, psychological, or geographical barriers
Conditions Lung Cancer Diagnosis, Colorectal Cancer...
Phase NA
Enrollment 1800
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The objective of the pragmatic trial to test the effectiveness of an existing, ongoing clinical service, the VA National TeleOncology program (NTO), a multilevel telehealth population health management program. The primary aims are to study the intervention and determine its effectiveness on telehealth engagement, clinical quality, and healthcare cost outcomes across personal characteristics.

Design

Study type: Interventional Phases: Allocation: Non Randomized Intervention model: Single Group Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Behavioral: National TeleOncology — Medical and/or subspecialty oncology care offered via facility-to-facility telehealth as an alternative to usual in-person care at the nearest VA or community oncology care setting offering similar services.

Primary Outcomes

  • Number of raw telehealth visits (Post-NTO implementation (up to 3 months))
  • Fraction of patients engaging in at least one telehealth visit (Post-NTO implementation (up to 3 months))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-06-18
Completion: 2027-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 1800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: NYU Langone Health
Collaborators: National Cancer Institute (NCI)
Principal Investigators:
  • Danil Makarov, MD, MHS (PRINCIPAL_INVESTIGATOR) - NYU Langone Health
Contact Information
Study Contact:
Janeth Juarez Padilla
646-501-3588
Janeth.juarezpadilla@nyulangone.org
Navid Dardashti
201-906-7713
Navid.dardashti@nyulangone.org
Interventions
  • Behavioral: National TeleOncology — Medical and/or subspecialty oncology care offered via facility-to-facility telehealth as an alternative to usual in-person care at the nearest VA or community oncology care setting offering similar services.
Study Locations (5 sites)
VA New York Harbor Healthcare System - Brooklyn, Brooklyn, New York 11209 United States
VA New York Harbor Healthcare System - St. Albans Community Living Center, Jamaica, New York 11425 United States
VA New York Harbor Health Care System - Manhattan, New York, New York 10010 United States
VA New York Harbor Healthcare System - Harlem Community Center, New York, New York 10027 United States
VA New York Harbor Healthcare System - Staten Island Community Clinic, Staten Island, New York 10314 United States
Eligibility Criteria
Patients Inclusion Criteria: 1. A Veteran 2. Aged 18 years or older 3. Newly diagnosed with lung, prostate, breast, or colon cancer within 3 months of telemedicine visit 4. Engaged in an oncology visit during the 36-month analysis period at a Veterans Affairs Medical Center (VAMC) location. VAMC Providers and Staff Inclusion Criteria: 1. Provider or staff member at one of the VAMC locations including physicians, nurse practitioners, physicians' assistants, and nurses caring for Veterans 2. Providers or staff members having helped provide care for at least 5 Veterans with cancer in the previous 6 months at a VAMC location Patients Exclusion Criteria: 1. Veterans who have not seen any providers in the VA within the past year 2. Patients previously diagnosed with lung, prostate, breast, or colon cancer 3. Pregnant patients VAMC Providers and Staff Exclusion Criteria: 1\. Providers or staff members who do not help treat Veterans with specified cancers in oncology at the VA
Conditions Cancer, Prostate Cancers, Breast Cancers...
Phase NA
Enrollment 740
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

EXCEL will provide online and, where feasible, in-person exercise programs to individuals living with and beyond cancer (ILWBC). Research has shown that targeted programs that include tailored exercise prescriptions are more successful in helping individuals with chronic disease to incorporate physical activity and exercise into their daily routines. While ILWBC are advised by healthcare professionals (HCPs) to engage in exercise, there is a lack of cancer-specific exercise programs and cancer-trained exercise specialists in Canada, outside of the research setting. Considering the negative impact cancer and its treatments have on fitness and physical activity levels, community-based efforts towards improving access, uptake and maintenance of exercise programming are needed. This study will evaluate the benefits of a community-based or online EXCEL exercise program for people living with and beyond cancer across Canada, using a streamlined intake process compared to the original EXCEL Study (HREBA.CC-20-0098, NCT04478851). This 8 to 12-week program (intervention) will be delivered in-person or over virtual platform. It includes twice weekly supervised exercise classes.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Group Exercise Classes — Participants will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting, twice weekly for a 8-12-week period (duration of intervention depends on scheduling logistics for the coordinating hubs and their spokes sites). The exercise sessions will be conducted in groups with a ratio of up to 15 participants per instructor. The program follows exercise progression principles (i.e., frequency, intensity, time, type, overload and progression) over the 8-12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits.

Primary Outcomes

  • Physical Activity Level (Baseline to one year)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-03-11
Completion: 2026-11-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 740 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Calgary
Collaborators: University of Alberta, Dalhousie University, Nova Scotia Health Authority, University of Toronto, Centre hospitalier de l'Université de Montréal (CHUM), University of British Columbia, Memorial University of Newfoundland, University of Prince Edward Island, Alberta Health services
Principal Investigators:
  • Nicole Culos-Reed, PhD (PRINCIPAL_INVESTIGATOR) - University of Calgary
Contact Information
Study Contact:
Julianna Dreger, PhD
(403) 210-8482
jdreger@ucalgary.ca
Georgia Kaluznick
403-210-8482
wellnesslab@ucalgary.ca
Julianna Dreger
403-210-8482
jdreger@ucalgary.ca
University of Calgary
Interventions
  • Behavioral: Group Exercise Classes — Participants will take part in a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting, twice weekly for a 8-12-week period (duration of intervention depends on scheduling logistics for the coordinating hubs and their spokes sites). The exercise sessions will be conducted in groups with a ratio of up to 15 participants per instructor. The program follows exercise progression principles (i.e., frequency, intensity, time, type, overload and progression) over the 8-12-weeks, with tailoring of any exercise to meet individual participant needs as required, in order to promote fitness and wellness benefits.
Study Locations (5 sites)
University of Calgary, Calgary, Alberta T2N1N4 Canada
University of British Columbia, Vancouver, British Columbia V6T 1Z7 Canada
Nova Scotia Health Authority, Halifax, Nova Scotia B3H 4R2 Canada
University of Toronto, Toronto, Ontario M5S 1A1 Canada
Centre hospitalier de l'Université de Montréal, Montreal, Quebec H2X 0A9 Canada
Eligibility Criteria
Inclusion Criteria: * have or had a diagnosis of cancer; * be 18 years or older; * be able to participate in low-intensity levels of activity, at minimum; * be pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), have received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, have a referral from their healthcare team indicating they have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise; * be able to provide informed written consent in English or French Exclusion Criteria: * does not or did not have a cancer diagnosis * is under the age of 18 * is unable to participate in mild exercise, at minimum * is not pretreatment, or receiving active cancer treatment (i.e., surgery, systemic therapy and radiation therapy), has not received cancer treatment within the past 3 years, or if beyond 3 years since treatment completion, doesn't have side effects from cancer treatment or the cancer itself, that could be improved or managed with exercise * unable to read/write in English * for online programs, does not have internet or computer access
Conditions Breast Cancer, Breast Adenocarcinoma
Phase Not Applicable
Enrollment 2000
Locations 13 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

The study is planned to observe and document the therapeutic decision-making process, treatment protocols, and clinical outcomes in patients with luminal breast cancer, whether they have undergone EndoPredict® testing or not

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Distant relapse free survival (DRFS) (5- and 10-years)
  • Overall Survival (OS) (5- and 10-years)
  • Distant relapse free interval (DRFI) (5- and 10-years)
  • Proportion of adjuvant chemotherapy administration and association with baseline clinicopathologic characteristics and EPclin score (Up to 2 months post-operatively)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-01
Completion: 2038-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 2000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: National and Kapodistrian University of Athens
Contact Information
Study Contact:
Michalis Kontos
+30 2132060800
michalis_kontos@yahoo.com
Georgios Metaxas
+30 2132051000
geometa@hotmail.com
"Elena Venizelou" General Hospital, Department of Surgery
Petros Charalampoudis
+30 2107483110
petros.charalampoudis@gmail.com
"Prolipsis" Center, Breast Unit
Interventions
N/A
Study Locations (13 sites)
"Elena Venizelou" General Hospital, Department of Surgery, Athens, Greece
"Prolipsis" Center, Breast Unit, Athens, Greece
Henry Dunant Hospital Center, 3rd Breast Surgical Department, Athens, Greece
Laiko Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece
Mediterraneo Hospital, Breast Clinic, Athens, Greece
Metropolitan General Hospital, 3rd Breast Clinic, Cholargós, Greece
Metropolitan General Hospital, 4th Breast Clinic, Cholargós, Greece
"Apollonio-Theotokos" General Clinic, Department of Surgery, Larissa, Greece
IASO Thessalias General Clinic, Breast Surgery Department, Larissa, Greece
IASO General Clinic, 2nd Breast Clinic, Marousi, Greece
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years old. * Histological diagnosis of invasive breast cancer. * T1-T3 tumor size. * 0-3 positive axillary lymph nodes. * Documented ER-positive tumor by immunohistochemistry (≥1% or Allred Score: ≥3/8 or H-score: ≥50/ 300) * Documented HER2-negative tumor by immunohistochemistry and/or in situ hybridization * Subject with signed and dated informed consent form. Exclusion Criteria: * History of another primary malignancy within the last 5 years, except for resected non-melanoma skin cancer. * Pre-operative chemotherapy administered. * Subject without signed and dated informed consent form.
Conditions Breast Cancer
Phase PHASE2
Enrollment 20
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Advanced hormone positive (HR+), HER2 negative breast cancer continues to pose a challenge when patients have progressed on CDK4/6 inhibitor and endocrine therapy leaving limited treatment options. Antibody-drug conjugates (ADCs) such as sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have changed practice due to significant improvement in progression free survival (PFS) and overall survival (OS) seen in this disease setting. There is a genuine interest to use SG sequentially after T-DXd, however there is no current prospectively curated evidence to support this strategy. Though the epitope is different, the payload are both topoisomerase I inhibitors. Thus, evidence is needed of both clinical efficacy and identification of mechanisms of sensitivity and resistance to sequential ADCs in HER-2 low MBC. It is hypothesized that performing whole genome and whole transcriptome sequencing in fresh tumour biopsies post progression of T-DXd and prior to SG in ER+/HER2 low metastatic breast cancer (MBC) will provide mechanistic insights into identifying biomarkers, and thus patients, sensitive to sequential SG.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Sacituzumab Govitecan — Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.

Primary Outcomes

  • Altered Tumor Genes by PFS Duration on SG Post T-DXd (Up to an average of 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2025-03-31
Completion: 2028-12-01
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 20 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: British Columbia Cancer Agency
Collaborators: Gilead Sciences
Contact Information
Study Contact:
Stephen Chia, MD
604-877-6000
schia@bccancer.bc.ca
Stephen Chia, MD
604-877-6000
schia@bccancer.bc.ca
BC Cancer - Vancouver Center
Interventions
  • Drug: Sacituzumab Govitecan — Administer Sacituzumab Govitecan (SG) at 10 mg/kg as an intravenous (IV) infusion on Days 1 and 8 of a 21-day cycle. SG should not be administered as an IV push or bolus.
Study Locations (1 sites)
BC Cancer - Vancouver Center, Vancouver, British Columbia V5Z4E6 Canada
Eligibility Criteria
Inclusion Criteria Patients must meet all of the following inclusion criteria to be eligible for participation in this study: 1. Willing and able to provide signed informed consent approved by UBC/BC Cancer REB 2. Female or male patients, regardless of race and ethnic group, who are ≥18 years old at the time of informed consent 3. Patients with locally advanced or metastatic ER+/HER2 low (defined as IHC 1+ or 2+ but FISH or CISH negative by ratio as per ASCO/CAP guidelines) breast cancer. Patients with imaging confirmed inoperable locally advanced breast cancer for which treatment is palliative in intent are also permitted. 4. Prior treatment must have included prior endocrine based treatment in the metastatic setting in conjunction with a CDK4/6 inhibitor. 5. Prior treatment must include at least 1 line of chemotherapy which must include trastuzumab deruxtecan (T-DXd) as the immediate prior line of therapy prior to study enrollment 6. The tumour must be accessible to be able to safely perform image guided biopsies for WGS and WTS. 7. Negative serum pregnancy test at baseline for pre-menopausal patients (within 14 days prior to randomization) and agreement to use medically approved precautions to prevent pregnancy during the study and for 12 weeks following the last dose of SG 8. Patients can have measurable or non measurable (but assessable) disease by CT or MRI as per RECIST Version 1.1 criteria as evaluated locally. Tumor lesions situated in a previously irradiated area are considered measurable if unequivocal progression has been documented in such lesions since radiation. 9. ECOG PS 0-2 10. Life expectancy ≥ 3 months 11. Acceptable bone marrow and organ function defined by the following laboratory values: 1. Absolute neutrophil count ≥1.0 x 109/L 2. Platelets ≥100 x 109/L 3. Hemoglobin ≥9.0 g/dL 4. INR ≤1.5 5. Serum creatinine clearance \>50 mL/min 6. In absence of liver metastases, direct bilirubin ≤1.5 x ULN, ALT and AST should be below ≤2.5 x ULN. If the patient has liver metastases, ALT and AST should be \< 5.0 x ULN. 12. Controlled brain metastasis (as per clinical determination) is allowed in the study at least 4 weeks before treatment. (Controlled brain metastasis is defined as no longer symptomatic from brain metastasis or no longer requiring higher doses of corticosteroids (\> 10 mg Dexamethasone per day) for CNS management. Anticonvulsants and stable corticosteroids dose can be included in the study). Exclusion Criteria Patients who meet any of the following exclusion criteria are not eligible to be enrolled in this study: 1. Patient is currently participating in any other type of medical research judged not to be scientifically or medically compatible with this study. 2. Patient has a known hypersensitivity to SG, irinotecan or its active metabolite SN-38. 3. Patients not available for follow up 4. Patients who are not willing to consider systemic treatment options 5. Tumor not accessible or not safe to perform biopsies 6. Patient has not had resolution of all acute toxic effects of prior anti-cancer therapy to CTCAE v. 5.0 grade ≤1 (except toxicities not considered a safety risk for the patient at investigators discretion: e.g. grade 2 peripheral neuropathy from prior chemotherapy that is stable). 7. Have an active second malignancy. Patients with a history of malignancy that has been completely treated, with no evidence of active cancer for 3 years prior to enrollment, or patients with surgically cured tumors with low risk of recurrence (e.g. non-melanoma skin cancer, histologically confirmed complete excision of carcinoma in situ, or similar) are allowed to enroll. 8. Have known active central nervous system (CNS) metastases. Patients with previously treated brain metastases may participate provided they have stable CNS disease (defined as no longer symptomatic from brain metastasis or no longer requires higher doses of corticosteroids (\> 10 mg Dexamethasone per day) for CNS symptom management. Anticonvulsants and stable corticosteroids dose can be included in the study). Screening for brain metastasis not required for enrollment. 9. Pregnancy and breast feeding 10. Patient without an adequate hematologic, renal and hepatic function as per above inclusion criteria 11. Patient has a pre-existing condition with uncontrolled diarrhea, chronic inflammatory bowel disease or GI perforation within 6 months prior to enrollment. 12. Have active serious infection requiring antibiotics.
Conditions Metastatic Breast Cancer
Phase Not Applicable
Enrollment 240
Locations 12 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

Planned study population consists of approximately 240 adult patients with HER2-positive mBC receiving anti-HER2 therapy in 12 oncological centers (in each center it is expected to recruit about 20 patients) in different regions in order to provide representative study sample. Patients will be included consecutively from the least recent diagnosis (within defined time period). Planned retrospective follow-up period for 1 patient is a period starting from the date of mBC diagnosis until end study or until patient's death, whichever occurs first. End of study will be at least 12 months after the latest date of mBC diagnosis to ensure all patients have the opportunity to contribute at least 12 months of data.

Design

Study type: Observational Observational model: Other Time perspective: Retrospective

Primary Outcomes

  • (1) To assess median PFS and PFS rate in patients with HER2-positive mBC receiving anti-HER2 therapy (except for trastuzumab deruxtecan) in routine practice in Kazakhstan (up to 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-06-12
Completion: 2026-12-31
Eligibility
Age: 18 Years – 99 Years
Sex: ALL
Volunteers: false
Enrollment: 240 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (12 sites)
Research Site, Oral, Kazakhstan 90005 Kazakhstan
Research Site, Aktobe, 30017 Kazakhstan
Research Site, Almaty, 50022 Kazakhstan
Research Site, Almaty, 50054 Kazakhstan
Research Site, Astana, 10000 Kazakhstan
Research Site, Astana, 10017 Kazakhstan
Research Site, Karaganda, 100019 Kazakhstan
Research Site, Petropavl, 150000 Kazakhstan
Research Site, Semey, 71407 Kazakhstan
Research Site, Shymkent, 160000 Kazakhstan
Eligibility Criteria
Inclusion Criteria: * Patients with HER2-positive mBC who are receiving or have started any anti-HER2 therapy (except for trastuzumab deruxtecan) at the time of inclusion * The diagnosis of mBC was established between the 1st January 2022 to 31st December 2023 * Patients with the availability of at least 24 months of follow-up data (from the date of mBC diagnosis) in the medical records at the participating site, unless patient died/moved or refused the therapy within the first 24 months of diagnosis * Age ≥18 years at the time of inclusion Exclusion Criteria: * Presence of other malignancies within the period from mBC diagnosis until the timepoint of data collection * Patients received trastuzumab deruxtecan * The participation in any interventional trial within period since diagnosis until the end of study
Conditions Breast Cancer, Cancer of the Breast
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-19
Study Details Design, interventions, and primary outcomes

About This Study

This is a subject registry study of patients who undergo cryoablation for their breast cancer after being determined not to be surgical candidates. Data collected as part of this registry will be used to assess the safety of percutaneous ultrasound-guided cryoablation in this population as well as provide long-term follow-up of subjects who received cryoablation.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Interventions / Regimen

  • Device: Cryoablation — Takes place at single time point.

Primary Outcomes

  • Proportion of patients who are free of serious treatment related complications per CTCAE v 5.0 (Through 3 year follow-up)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-07-26
Completion: 2031-07-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Washington University School of Medicine
Principal Investigators:
  • Heather Garrett, M.D. (PRINCIPAL_INVESTIGATOR) - Washington University School of Medicine
Contact Information
Study Contact:
Heather Garrett, M.D.
314-454-5206
hvgarrett@wustl.edu
Heather Garrett, M.D.
314-454-5206
hvgarrett@wustl.edu
Washington University School of Medicine
Heather Garrett, M.D.
Washington University School of Medicine
Interventions
  • Device: Cryoablation — Takes place at single time point.
Study Locations (1 sites)
Washington University School of Medicine, St Louis, Missouri 63110 United States
Eligibility Criteria
Eligibility Criteria: * Diagnosis of breast cancer. * Mass must be visible on ultrasound and \> 5 mm from skin. * Not undergoing surgery, because: * Patient has a medical condition that would not allow sedation or general anesthesia * Surgery is not clinically indicated due to unresectable and/or metastatic disease * Surgery is not clinically indicated for another reason * Patient declines surgery * At least 18 years old. * Able to understand and willing to sign an IRB-approved written informed consent document.